spacer
home > pmps > winter 2017 > formulating a plan
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Formulating a Plan

High doses are often necessary to deliver enough of an orally administered drug to the lungs or nasal passages through the bloodstream. As many medicines are now highly potent, delivery by mouth has the potential to cause severe side effects. Combined with this, when products are taken in this way they are easily metabolised, which means that they are not always adequately administered to the nose or lungs, thus limiting the success of the treatment.

In contrast, inhalation formulations enable pharmaceuticals to be delivered directly to the nasal passages or lungs in smaller doses, reducing the risks of both side effects and drug-to-drug interaction. Their growth in popularity can further be attributed to their ability to give the most direct access to a drug target. For example, many inhaled products are steroid drug classes. They can have a harmful impact on growth and hormone balance if taken in large amounts by children and is, therefore, beneficial to deliver a smaller dose to the site of action.

These local therapies offer fast absorption, rapid response and enable a drug to be administered straight to the conducting zone of the lungs. As a result, they work particularly well for conditions such as asthma. Inhalation also represents a very attractive way to deliver drugs to the brain. In the treatment of migraines, for instance, nasal spray drug delivery into the nose can bring fast and effective relief.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Poonam Aliyah Sheth is a Research Scientist specialising in inhalation product development at Recipharm and she holds a PhD in Pharmaceutical Science from the University of Arizona, US. With particular expertise in MDI formulations, dry powder inhalers and nebulised formulations, she has been integral to the development and manufacture of many original and generic products for inhalation drug delivery for global clients, ranging from emerging to large pharmaceutical organisations.

Ramil Menzeleev, PhD, is Director of Recipharm’s Analytical Sciences department. He oversees analytical method development, providing scientific review for client projects while also participating in the design and development of electronic data recording software platforms. A specialist in analytical chemistry, his expertise covers fast, highly sensitive, accurate and high-throughput quantitation method development. He also manages the selection and implementation of IT solutions, including software for business process management, as well as review and approval software for design, validation, implementation and use in Good Manufacturing Practice environments.
spacer
Poonam Aliyah Sheth
spacer
spacer
spacer
Ramil Menzeleev
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Applikon Biotechnology collaborates with Emerson for new Life Sciences R&D solution: V-Control

Applikon Biotechnology has launched V-Control for R&D scale bioreactors, a sophisticated automation solution developed in collaboration with Emerson. It uses a scaled version of Emerson’s DeltaV distributed control system (DCS), DeltaV Discovery, designed for research and discovery laboratories. V-Control enables easy process control and data up-scaling in one platform. Furthermore, it provides organizations that already use the DeltaV DCS at production scale with reliable automation scaled to fit the needs of the laboratory environment, making tech transfer easier.
More info >>

White Papers

Clinical Trials in Ukraine: Orange Paper Overview and 1st Half Year 2014

Synergy Research Group

The Orange Paper is an analytical report about the clinical trials market in Russia, published quarterly by the contract research organization Synergy Research Group. The first edition of Orange Paper was released in 2006, and at the moment 31 issues have already published. Now, thanks to Synergy Group Ukraine, obtaining information about the market of clinical trials in Ukraine has become possible. In Ukraine, during the period from 1996 to 2013, applicants had obtained 3,864 positive conclusions about the possibility of conducting clinical trials of drugs, both for domestic and foreign manufacturers, including conduct of multinational multi-center clinical trials (hereinafter – MMCTs)
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement